123 related articles for article (PubMed ID: 20425764)
21. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
Sommer W; Heilig M
Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
[TBL] [Abstract][Full Text] [Related]
22. [Antisense oligonucleotides arrest the synthesis of disease promoting proteins].
Schnädelbach S
Med Monatsschr Pharm; 1998 Dec; 21(12):394-5. PubMed ID: 9925458
[No Abstract] [Full Text] [Related]
23. [Applications of antisense oligonucleotides in oncology].
Pierga JY; Cammilleri S; Benyahia B; Magdelénat H
Bull Cancer; 1994 Dec; 81(12):1023-42. PubMed ID: 7742591
[TBL] [Abstract][Full Text] [Related]
24. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
25. Technology evaluation: AVI-4126, AVI BioPharma.
Stephens AC
Curr Opin Mol Ther; 2004 Oct; 6(5):551-8. PubMed ID: 15537057
[TBL] [Abstract][Full Text] [Related]
26. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
27. Cancer therapy finds a solid target.
Secko D
CMAJ; 2005 Aug; 173(3):246. PubMed ID: 16076816
[No Abstract] [Full Text] [Related]
28. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
29. Antisense molecules for targeted cancer therapy.
Wacheck V; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
[TBL] [Abstract][Full Text] [Related]
30. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method.
Yildiz D; Oztas H; Hilal Ates B
Med Hypotheses; 2005; 64(2):328-32. PubMed ID: 15607566
[TBL] [Abstract][Full Text] [Related]
31. Antisense approaches to cancer gene therapy.
Mercola D; Cohen JS
Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
[TBL] [Abstract][Full Text] [Related]
32. Targeting the Bcl-2 family in cancer therapy.
Papadopoulos K
Semin Oncol; 2006 Aug; 33(4):449-56. PubMed ID: 16890799
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of peritoneal dissemination in human gastric cancer by MMP-7-specific antisense oligonucleotide.
Yonemura Y; Endo Y; Fujita H; Kimura K; Sugiyama K; Momiyama N; Shimada H; Sasaki T
J Exp Clin Cancer Res; 2001 Jun; 20(2):205-12. PubMed ID: 11484976
[TBL] [Abstract][Full Text] [Related]
34. [Oncogenes and pharmacological approaches to cancer therapy].
Tocque B
Pathol Biol (Paris); 1992 Nov; 39(9):869-70. PubMed ID: 1538914
[No Abstract] [Full Text] [Related]
35. Antisense oligonucleotides.
Herdewijn P
Verh K Acad Geneeskd Belg; 1996; 58(4):359-81. PubMed ID: 8956554
[TBL] [Abstract][Full Text] [Related]
36. The role of antisense oligonucleotides in the treatment of bladder cancer.
Duggan BJ; Gray S; Johnston SR; Williamson K; Miyaki H; Gleave M
Urol Res; 2002 Jul; 30(3):137-47. PubMed ID: 12111175
[TBL] [Abstract][Full Text] [Related]
37. Bcl-2 family members as molecular targets in cancer therapy.
Marzo I; Naval J
Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
[TBL] [Abstract][Full Text] [Related]
38. Antisense oligonucleotide technology in the development of cancer therapeutics.
Tseng BY; Brown KD
Cancer Gene Ther; 1994 Mar; 1(1):65-71. PubMed ID: 7621240
[No Abstract] [Full Text] [Related]
39. Antisense tumor therapy (a dream under construction).
Kopper L; Kovalszky I
In Vivo; 1994; 8(5):781-6. PubMed ID: 7727725
[TBL] [Abstract][Full Text] [Related]
40. [Oligonucleotide therapeutics].
Matsuda Y; Nakamura Y
Nihon Rinsho; 2012 Nov; 70 Suppl 8():393-7. PubMed ID: 23513872
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
